NEW YORK (GenomeWeb) – Cresset said this week that Polish drug discovery company Selvita has licensed two of its software products for use in its drug research and development efforts.
Specifically, Cresset said that Selvita has licensed its Forge and Spark software products, which provide tools for applications such as SAR analysis, ligand-based molecular design, and bioisosteric replacement.
"We are currently focused on target-based design, however, as requirements of our projects change, we need to include ligand based approaches in the methods we use," Mariusz Milik, Selvita's head of computational chemistry said in a statement. "We anticipate using Cresset's software as a key component in our discovery chemistry capabilities."
For example, David Bardsley, Cresset’s commercial director, said in a statement that "the Spark reagent databases will enable them to inform synthetic decisions, whilst Forge will give control and insight into their activity data enabling them to plan the direction of their projects with confidence."
Bardsley also added that Cresset is "delighted to see growth in the emerging drug discovery market of Central and Eastern Europe."
Financial and other terms of the licensing agreement were not disclosed.